Ionis Pharmaceuticals, Inc.
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-381.4M | $-453.9M | $-366.3M | $-269.7M | $-28.6M | $-444.3M | $278.1M | $273.7M |
| Depreciation & Amortization | — | — | — | — | — | — | — | — |
| Depreciation | $10.0M | $9.6M | $10.3M | $14.3M | $15.5M | $13.4M | $12.5M | $10.7M |
| Amortization | $2.4M | $2.3M | $2.6M | $2.4M | $2.4M | $2.1M | $1.9M | $1.8M |
| Stock-Based Compensation | $133.9M | $130.2M | $105.8M | $100.3M | $120.7M | $230.1M | $146.6M | $131.3M |
| Net Cash from Operating Activities | $-268.6M | $-500.9M | $-307.5M | $-274.4M | $30.8M | $35.9M | $345.6M | $602.9M |
| Investing Activities | ||||||||
| Capital Expenditures | $51.4M | $45.3M | $23.8M | $15.7M | $12.0M | $35.1M | $30.9M | $13.6M |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | $-277.8M | $-134.0M | $-214.1M | $-262.6M | $194.9M | $274.5M | $-41.3M | $-929.6M |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | $0 | $0 | $90.5M | $34.4M | $0 |
| Net Cash from Financing Activities | $675.8M | $478.1M | $644.1M | $-55.3M | $245.9M | $-596.6M | $100.0M | $475.9M |
| Net Change in Cash | $130.2M | $-157.2M | $122.8M | $-592.7M | $471.5M | $-285.6M | $404.5M | $149.2M |
| Free Cash Flow | $-320.0M | $-546.2M | $-331.3M | $-290.1M | $18.8M | $772.0K | $314.7M | $589.3M |